RÉSUMÉ
We report the first instance of macrolide resistance developing in vivo following appropriate antibiotic use in a healthy volunteer as a part of a controlled human infection with Campylobacter jejuni. In vivo development of macrolide resistance may be an important contributor to antibiotic resistance in C. jejuni.
Sujet(s)
Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Infections à Campylobacter/traitement médicamenteux , Campylobacter jejuni/effets des médicaments et des substances chimiques , Résistance bactérienne aux médicaments , Macrolides/pharmacologie , Macrolides/usage thérapeutique , Techniques de typage bactérien , Infections à Campylobacter/microbiologie , Campylobacter jejuni/classification , Campylobacter jejuni/génétique , Campylobacter jejuni/isolement et purification , Profilage d'ADN , ADN bactérien/génétique , Électrophorèse en champ pulsé , Volontaires sains , Humains , Mâle , Tests de sensibilité microbienne , Jeune adulteRÉSUMÉ
M01ZH09, S. Typhi (Ty2 Delta aroC Delta ssaV) ZH9, is a single oral dose typhoid vaccine with independently attenuating deletions. A phase II randomized, double-blind, placebo-controlled, dose-escalating trial evaluated the safety and immunogenicity of M01ZH09 to 1.7 x 10(10) colony-forming units (CFU). 187 Healthy adults received vaccine or placebo in four cohorts. Serologic responses and IgA ELISPOT were measured. At all doses, the vaccine was well tolerated and without bacteremias. One subject had a transient low-grade fever. 62.2-86.1% of subjects seroconverted S. Typhi-specific LPS IgG and 83.3-97.4% IgA; 92.1% had a positive S. Typhi LPS ELISPOT. M01ZH09 is safe and immunogenic up to 1.7 x 10(10)CFU. Efficacy testing of this single-dose oral typhoid vaccine is needed.
